Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5083558
Max Phase: Preclinical
Molecular Formula: C38H70N12O9
Molecular Weight: 839.05
Molecule Type: Unknown
Associated Items:
ID: ALA5083558
Max Phase: Preclinical
Molecular Formula: C38H70N12O9
Molecular Weight: 839.05
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
Standard InChI: InChI=1S/C38H70N12O9/c1-20(2)18-27(33(54)44-23(6)31(52)47-26(37(58)59)13-10-16-43-38(41)42)48-32(53)24(7)45-34(55)28(19-21(3)4)49-35(56)29-14-11-17-50(29)36(57)25(12-8-9-15-39)46-30(51)22(5)40/h20-29H,8-19,39-40H2,1-7H3,(H,44,54)(H,45,55)(H,46,51)(H,47,52)(H,48,53)(H,49,56)(H,58,59)(H4,41,42,43)/t22-,23+,24-,25-,26-,27-,28-,29-/m0/s1
Standard InChI Key: PEAOFINUIBSJJP-IPQAMJNRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 839.05 | Molecular Weight (Monoisotopic): 838.5389 | AlogP: -2.16 | #Rotatable Bonds: 26 |
Polar Surface Area: 346.15 | Molecular Species: ZWITTERION | HBA: 11 | HBD: 12 |
#RO5 Violations: 3 | HBA (Lipinski): 21 | HBD (Lipinski): 15 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.94 | CX Basic pKa: 11.59 | CX LogP: -4.37 | CX LogD: -7.61 |
Aromatic Rings: 0 | Heavy Atoms: 59 | QED Weighted: 0.03 | Np Likeness Score: 0.04 |
1. Gorman DM, Li XX, Lee JD, Fung JN, Cui CS, Lee HS, Rolfe BE, Woodruff TM, Clark RJ.. (2021) Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity., 64 (22.0): [PMID:34762432] [10.1021/acs.jmedchem.1c01174] |
Source(1):